Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China.
NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China.
Transl Vis Sci Technol. 2022 Apr 1;11(4):23. doi: 10.1167/tvst.11.4.23.
To investigate the clinical outcomes in small incision lenticule extraction (SMILE) and EVO implantable Collamer lens (ICL)-treated high myopia.
Thirty-three SMILE-treated and 32 EVO ICL-treated patients were included and followed up for 6 months. Subjective refraction, contrast sensitivity, and disk halo size were measured preoperatively and postoperatively. Patient-reported outcomes (PROs) were obtained at the final visit.
Significant differences in efficacy and safety indices were observed between the SMILE and EVO ICL groups at 6 months postoperatively (P < 0.05). In the SMILE group, the mesopic contrast sensitivity at 2.2 cycles per degree (cpd) and photopic contrast sensitivity at 0.5, 3.4, and 7.1 cpd were significantly improved. In the EVO ICL group, the mesopic contrast sensitivity at 7.1 cpd and photopic contrast sensitivity at 0.5, 7.1, and 14.6 cpd were significantly improved. The halo radii after SMILE were significantly increased at 1 week, showed a decreasing trend at 1 month, returned to baseline at 3 months, and progressed stably at 6 months. However, it was unchanged in the EVO ICL group. Regarding subjective experience, haloes were the most common disturbance with mild and little bothersomeness after EVO ICL in contrast to starbursts after SMILE.
EVO ICL implantation yielded better visual outcomes, improved contrast sensitivity particularly at high spatial frequencies, had a stabler disk halo size, and increased incidence of haloes, with less influence than that of SMILE.
The disk halo and PRO findings will be of benefit for consultations and evaluations in visual performance and disturbances.
探讨小切口微透镜提取术(SMILE)和可植入式隐形眼镜(EVO ICL)治疗高度近视的临床疗效。
纳入 33 例 SMILE 治疗患者和 32 例 EVO ICL 治疗患者,并进行了 6 个月的随访。术前和术后分别测量主观屈光、对比敏感度和盘光晕大小。在最后一次就诊时获得患者报告的结果(PROs)。
术后 6 个月,SMILE 组和 EVO ICL 组在疗效和安全性指标方面存在显著差异(P<0.05)。在 SMILE 组,2.2 周/度的中空间对比敏感度和 0.5、3.4 和 7.1 周/度的高空间对比敏感度显著提高。在 EVO ICL 组,7.1 周/度的中空间对比敏感度和 0.5、7.1 和 14.6 周/度的高空间对比敏感度显著提高。SMILE 术后 1 周盘光晕半径明显增大,1 个月时呈下降趋势,3 个月时恢复基线,6 个月时稳定进展。然而,EVO ICL 组的盘光晕大小则无变化。在主观体验方面,EVO ICL 术后光晕是最常见的干扰,表现为轻度和轻微不适,而 SMILE 术后则表现为星爆。
EVO ICL 植入术可获得更好的视觉效果,提高特别是高空间频率的对比敏感度,盘光晕大小更稳定,光晕发生率增加,但对视觉干扰的影响小于 SMILE。
医学领域的博士